(Q38804315)

6 September 2017

Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer (English)

1 reference

6 September 2017

1 reference

Cherifa Ayari

1

1 reference

6 September 2017

Marjorie Besançon

2

1 reference

6 September 2017

Alain Bergeron

3

1 reference

6 September 2017

Hélène LaRue

4

1 reference

6 September 2017

Vanessa Bussières

5

1 reference

6 September 2017

Yves Fradet

6

1 reference

6 September 2017

12 January 2016

1 reference

Cancer Immunology, Immunotherapy

6 September 2017

1 reference

6 September 2017

65

1 reference

6 September 2017

223-234

1 reference

6 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-015-1789-y

6 September 2017

0 references

cites work

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

TLR3 agonists as immunotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Trial Watch: Toll-like receptor agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Toll-like receptors and their crosstalk with other innate receptors in infection and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

TLR3 can directly trigger apoptosis in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

The uroepithelium: not just a passive barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Toll-like receptors in normal and malignant human bladders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Adenovirus inhibition of cellular protein synthesis is prevented by the drug 2-aminopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

MAGE-A9 mRNA and protein expression in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

The CDK Network: Linking Cycles of Cell Division and Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Regulatory T cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

The development and function of memory regulatory T cells after acute viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

TLR3: interferon induction by double-stranded RNA including poly(I:C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1789-Y

10.1007/S00262-015-1789-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

0 references

1 reference